Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells

• Published in: Nephrology, dialysis, transplantation dialysis, transplantation, 2004-04, Vol.19 (4), p.917-924
• Main Authors: Witowski, Janusz, Korybalska, Katarzyna, Książek, Krzysztof, Wiśniewska-Elnur, Justyna, Jörres, Achim, Lage, Cristina, Schaub, Thomas P., Passlick-Deetjen, Jutta, Bręborowicz, Andrzej, Grzegorzewska, Alicja, Książek, Andrzej, Liberek, Tomasz, Lichodziejewska-Niemierko, Monika, Majdan, Maria, Rutkowski, Bolesław, Stompór, Tomasz, Sułowicz, Władysław
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; biocompatibility; Biological and medical sciences; Cell Division; Cells, Cultured; Emergency and intensive care: renal failure. Dialysis management; Epithelial Cells; Female; Glomerulonephritis; Glucose - administration & dosage; glucose degradation products; Hemodialysis Solutions; Humans; Intensive care medicine; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Peritoneal Dialysis; peritoneal mesothelial cells; Peritoneum - cytology; Randomized Controlled Trials as Topic; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system
• ISSN: 0931-0509; 1460-2385
• DOI: 10.1093/ndt/gfh013

Background.In vitro experiments point to a better biocompatibility profile of new pH-neutral peritoneal dialysis fluids (PDFs) containing low levels of glucose degradation products (GDPs). The present study examines the impact on human peritoneal mesothelial cells (HPMCs) of equilibrated dialysates obtained during dialysis with either conventional or new PDFs. Methods. Peritoneal dialysate was collected from 17 patients participating in a randomized, controlled, cross-over trial comparing a pH-neutral low-GDP solution (Balance) to a conventional solution (S-PDF). All patients were treated sequentially for 3 months with both PDFs. At the end of each treatment phase, peritoneal effluent was drained after a timed 10 h dwell. Samples of dialysate were then mixed with standard culture medium and added to in vitro cultures of HPMCs from healthy donors. Cells were assessed for proliferation, viability and cytokine release. Results. Proliferation and viability of HPMCs were better preserved in the presence of effluent obtained during dialysis with Balance (P